Drug intelligence / Profile preview

Lu AE04621

Development stage: Phase 1
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

Lu AE04621 is a small molecule drug developed by Lundbeck as a dopaminergic agent for the treatment of Parkinson's disease. It acts as an agonist at dopamine receptors, specifically targeting D1 and D2 subtypes, and is considered a prodrug of catecholamine. The compound was designed to modulate dopamine signaling in brain regions affected by Parkinson's disease, with the aim of providing improved symptom control compared to conventional therapies. Lu AE04621 completed phase 1 clinical trials but has not advanced further in development or received regulatory approval[1][2][3][5][7].

Other names: Lu AA40326

Targets

DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on Lu AE04621.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AE04621.

Explore the full profile